|
|
|
|
|
|
|
HIGHLIGHTS FROM THE 2024 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING |
|
|
|
|
| Advanced Sequencing and Targeted Therapy Strategies in Renal Cell Carcinoma: How Can We Help More Patients Not at the Expense of Toxicity?
|
| Yu-Wei Chen, MD, MS
|
| Yu-Wei Chen discussed the evolving treatment strategies for metastatic RCC, highlighting the importance of sequencing therapies to avoid cross-resistance and the potential benefits of combining VEGF-TKIs and immune checkpoint inhibitors in the post-IO setting. He emphasized the critical role of early integration of palliative care and the need for strategies to manage treatment-related medical and financial toxicities to improve patient outcomes.
|
|
|
|
|
|
| Avelumab as Neoadjuvant Therapy in Patients with Muscle-Invasive Urothelial Carcinoma: Survival Data of AURA Trial, Oncodistinct 004
|
| Jeremy Blanc, MD
|
| Jeremy Blanc presented the survival analysis of the AURA trial evaluating avelumab as neoadjuvant therapy in patients with muscle-invasive urothelial carcinoma. AURA is a multi-center, non-comparative randomized phase II trial investigating neoadjuvant avelumab alone or in combination with chemotherapy.
|
|
|
|
|
|
| Camrelizumab plus Apatinib for Previously Treated Advanced Adrenocortical Carcinoma: A Single-Arm, Open-Label, Phase 2 Trial
|
| Zhigong Wei, MD
|
| Zhigong Wei presented the phase II trial results showing that camrelizumab combined with apatinib demonstrated a 52% objective response rate in previously treated advanced adrenocortical carcinoma patients. The study reported a median progression-free survival of 12.6 months and median overall survival of 20.9 months, with manageable safety profiles. The findings suggest that this combination therapy is promising and warrants further evaluation.
|
|
|
|
|
|
| A Multi-Institution Analysis of Outcomes With First-Line Systemic Therapy for 102 Patients With Metastatic Chromophobe Renal Cell Carcinoma |
| Sahil Doshi, MD |
| Sahil Doshi presented a multi-institutional retrospective analysis on first-line systemic therapies for 102 patients with metastatic chromophobe renal cell carcinoma. The study, which included patients from MSKCC, MDACC, and Johns Hopkins, found that doublet therapies (VEGF/TKI + mTORi or TKI + IO) were associated with longer median time to treatment failure (17 and 15 months, respectively) and overall survival (99 and 56 months, respectively) compared to single-agent therapies. |
|
|
|
|
|
| Preliminary Safety, Pharmacokinetics and Clinical Activity of DFF332, an Oral HIF2α Inhibitor, as Monotherapy in a Phase 1 Dose Escalation Study in Patients with Advanced Clear Cell RCC
|
| Sumanta K. Pal, MD, FASCO
|
| Monty Pal presented a phase I dose-escalation study of DFF332 in patients with advanced ccRCC. The study demonstrated that DFF332 was well tolerated with no dose-limiting toxicities, showing a disease control rate of 52.5%, including partial responses in 5% of patients and stable disease in 47.5%. Pharmacokinetic analysis revealed fast oral absorption and slow elimination, with the most common adverse events being fatigue and anemia.
|
|
|
|
|
|
|
|
|
|
|
| Systemic Treatments in Favorable and Very Favorable Risk Metastatic Renal Cell Carcinoma: Real World Evidence from the International mRCC Database Consortium
|
| Martin Zarba, MD
|
| Martin Zarba presented a real-world analysis from the International mRCC Database Consortium (IMDC) on systemic treatments for favorable and very favorable risk metastatic renal cell carcinoma. The study found no significant differences in two-year overall survival between patients treated with VEGF inhibitors (VEGFi), ipilimumab + nivolumab, or IO + VEGFi combinations.
|
|
|
|
|
|
| Investigation of T Cell Phenotypes Associated with Response or Resistance to Immune Checkpoint Inhibitors Through Single-Cell Analysis of Renal Cell Carcinoma
|
| Soki Kashima, MD, Ph.D.
|
| Soki Kashima presented findings from a single-cell analysis of renal cell carcinoma to investigate T cell phenotypes associated with response or resistance to immune checkpoint inhibitors. The study revealed significant heterogeneity among CD8+ T cells, particularly exhausted T cells.
|
|
|
|
|
|
|
|
|
|
|
